Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewAIDS/HIVCardiology Open Access | 10.1172/jci.insight.198647

Atorvastatin suppresses HIV/antiretroviral drug-induced cardiac fibrosis and dysfunction in mice by blocking platelet TGFβ1 signaling

Kumar Subramani,1 Denys Babii,1 Brienne Cole,1 Tayyab A. Afzal,1 Thamizhiniyan Venkatesan,1 Trevor Word,1 Sandra Gostynska,1 Sixia Chen,1 Kar-Ming Fung,1 Ali Danesh,2 Itzayana G. Miller,2 Paul Klotman,3 Brad R. Jones,2 Jeffrey Laurence,4 and Jasimuddin Ahamed1

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Subramani, K. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Babii, D. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Cole, B. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Afzal, T. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Venkatesan, T. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Word, T. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Gostynska, S. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Chen, S. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Fung, K. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Danesh, A. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Miller, I. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Klotman, P. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Jones, B. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Laurence, J. in: PubMed | Google Scholar

1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, United States of America

2Division of Infectious Diseases, Weill Cornell Medical College, New York, United States of America

3Baylor College of Medicine, Houston, United States of America

4Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, United States of America

Find articles by Ahamed, J. in: PubMed | Google Scholar

Published February 6, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.198647.
Copyright © 2026, Subramani et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published February 6, 2026 - Version history
View PDF
Abstract

Cardiovascular disease (CVD), both atherosclerosis-related and heart failure with preserved ejection fraction (HFpEF) linked to cardiac fibrosis, contributes to morbidity and mortality in people with HIV (PWH) receiving antiretroviral therapy (ART). In the REPRIEVE trial, pitavastatin reduces atherosclerotic CVD risk to a magnitude inconsistent with pitavastatin’s impact solely on LDL-cholesterol and inflammation. We hypothesized that HFpEF in PWH is related to HIV-induced fibrosis mediated by platelet TGFβ1, is accelerated by certain contemporary ART, and may also be inhibited by statins. ART drugs used in REPRIEVE, including a nucleoside/nucleotide, integrase inhibitor-based regimen (tenofovir (TDF), emtricitabine (FTC), and dolutegravir (DTG)), and the protease inhibitors ritonavir (RTV) and darunavir (DRV), and the impact of atorvastatin, were examined in two HIV mouse models: transgenic HIV-Tg26 mice and HIV-PDX mice engrafted with T cells isolated from PWH. HIV-Tg26 and HIV-PDX mice had higher cardiac fibrosis than littermate controls without HIV (p<0.05). Administration of TDF-FTC-DTG or RTV, but not DRV, resulted in a further ~2-fold increase in fibrosis (p<0.01). Cardiac fibrosis and intracardiac fat accumulation correlated with reduced diastolic function. Mice depleted of platelet TGFβ1 (TGFβ1Platelet-ΔTg26), or treated with atorvastatin, were partially protected from HIV- and ART-induced cardiac fibrosis, steatosis, and diastolic dysfunction. Atorvastatin effects were independent of changes in inflammatory cytokines. These effects correlated with reduced platelet activation and TGFβ signaling in cardiac endothelial cells, fibroblasts, and macrophages undergoing mesenchymal transition. Our results indicate that certain ART regimens accelerate HIV-associated CVD characterized by HFpEF via platelet TGFβ1-dependent processes, which were mitigated by atorvastatin. We postulate that our findings provide a potential mechanism for the pleiotropic effects of statins in HIV/ART-linked CVD which could be targeted by antiplatelet agents or inhibition of TGFβ signaling.

Graphical Abstract
graphical abstract
Supplemental material

View

Version history
  • Version 1 (February 6, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts